LU91297I2 - Vaccin rotavirus (vivant,solution buvable) et ses dérivés pharmaceutiquement acceptable (rotateq) - Google Patents

Vaccin rotavirus (vivant,solution buvable) et ses dérivés pharmaceutiquement acceptable (rotateq)

Info

Publication number
LU91297I2
LU91297I2 LU91297C LU91297C LU91297I2 LU 91297 I2 LU91297 I2 LU 91297I2 LU 91297 C LU91297 C LU 91297C LU 91297 C LU91297 C LU 91297C LU 91297 I2 LU91297 I2 LU 91297I2
Authority
LU
Luxembourg
Prior art keywords
rotateq
live
pharmaceutically acceptable
acceptable derivatives
oral solution
Prior art date
Application number
LU91297C
Other languages
English (en)
Original Assignee
Wistar Inst
Philadelphia Children Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Inst, Philadelphia Children Hospital filed Critical Wistar Inst
Publication of LU91297I2 publication Critical patent/LU91297I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
LU91297C 1987-11-30 2006-12-20 Vaccin rotavirus (vivant,solution buvable) et ses dérivés pharmaceutiquement acceptable (rotateq) LU91297I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12647787A 1987-11-30 1987-11-30

Publications (1)

Publication Number Publication Date
LU91297I2 true LU91297I2 (fr) 2007-02-20

Family

ID=22425038

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91297C LU91297I2 (fr) 1987-11-30 2006-12-20 Vaccin rotavirus (vivant,solution buvable) et ses dérivés pharmaceutiquement acceptable (rotateq)

Country Status (12)

Country Link
EP (1) EP0323708B1 (fr)
JP (1) JP2818760B2 (fr)
AT (1) ATE128873T1 (fr)
AU (1) AU618973B2 (fr)
CA (1) CA1303525C (fr)
DE (2) DE122006000071I1 (fr)
ES (1) ES2079358T3 (fr)
GR (1) GR3018262T3 (fr)
IL (1) IL88534A (fr)
LU (1) LU91297I2 (fr)
NL (1) NL300252I2 (fr)
ZA (1) ZA888931B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU618963B2 (en) * 1987-08-07 1992-01-16 Institut Pasteur Vaccines whose characteristic epitope is incorporated into a protein of picornavirus, in particular, poliovirus
US5626851A (en) * 1987-11-30 1997-05-06 The Wistar Institute Of Anatomy And Biology Rotavirus reassortant vaccine
DE69130206T2 (de) * 1990-07-26 1999-03-04 Wistar Inst Impfstoff aus reassortiertem rotavirus
US5610049A (en) * 1991-05-01 1997-03-11 The Wistar Institute Of Anatomy And Biology Human rotavirus HCR3A and method of growing said rotavirus
US5900238A (en) * 1995-07-27 1999-05-04 Immunex Corporation Vaccine delivery system
US6110724A (en) * 1996-10-18 2000-08-29 The Research Foundation For Microbial Diseases Of Osaka University Rotavirus antigen, vaccine and diagnostic agent for rotavirus infections, and a method for producing the antigen
CN110903403B (zh) * 2019-12-16 2021-07-13 中国农业大学 一种牛轮状病毒嵌合抗原以及检测牛轮状病毒抗体的胶体金免疫层析试纸卡
KR102374547B1 (ko) * 2021-05-31 2022-03-14 에스케이바이오사이언스(주) 재배열 로타바이러스의 제조 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4571385A (en) * 1983-06-27 1986-02-18 The United States Of America As Represented By The Department Of Health And Human Services Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors
US4636385A (en) * 1985-02-15 1987-01-13 The Wistar Institute Of Anatomy & Biology Vaccine, method for its preparation, and use thereof in vaccinating humans against rotavirus infection

Also Published As

Publication number Publication date
IL88534A0 (en) 1993-12-08
NL300252I1 (nl) 2007-01-01
GR3018262T3 (en) 1996-02-29
DE3854575T2 (de) 1996-05-15
ES2079358T3 (es) 1996-01-16
ZA888931B (en) 1989-07-26
JP2818760B2 (ja) 1998-10-30
ATE128873T1 (de) 1995-10-15
NL300252I2 (nl) 2007-06-01
DE3854575D1 (de) 1995-11-16
EP0323708B1 (fr) 1995-10-11
JPH02138970A (ja) 1990-05-28
AU2630688A (en) 1989-06-01
CA1303525C (fr) 1992-06-16
EP0323708A1 (fr) 1989-07-12
IL88534A (en) 1994-02-27
DE122006000071I1 (de) 2007-04-05
AU618973B2 (en) 1992-01-16

Similar Documents

Publication Publication Date Title
LU91297I2 (fr) Vaccin rotavirus (vivant,solution buvable) et ses dérivés pharmaceutiquement acceptable (rotateq)
NO20015073L (no) Vaksiner
FI892131A0 (fi) Analoger till underenheter av bordetellatoxin, vilka haerstammar fraon hybrid-dna.
WO2003003941A3 (fr) Vaccin monodose a base de mycoplasma hyopneumoniae
NZ209051A (en) Orally administered immunogenic composition including live, encysted parasitic protozoa embedded within a firmly-set gel matrix
EP0192404A3 (fr) Vaccin, méthode de préparation et son utilisation pour la vaccination d'humains contre une infection à rotavirus
JP2003507040A5 (fr)
Zapikian et al. Alternative approaches to the development of a rotavirus vaccine.
DK0493575T3 (da) Vaccine af reassortant rotavirus
DE69629812D1 (de) Impfstoff gegen rotavirus infektionen enthaltend peptide des viralenterotoxines nsp4
DK0626008T3 (da) Vaccine, der som en adjuvans indeholder acemannan
EP1237573B1 (fr) Utilisation de proteines immunogenes immunosuppressives ou angiogeniques rendues inactives pour la production d'lga secretoires
Cohen et al. Two injections of diphtheria-tetanus-pertussis-polio vaccine as the backbone of a simplified immunization schedule in developing countries
Levine et al. Future vaccines against enteric pathogens
MY137709A (en) Method for obtaining antigenic structures of high cross reactivity and their use in formulations
AU784344B2 (en) Compositions and method for preventing reactogenicity associated with administration of immunogenic live rotavirus compositions
FR2796282B1 (fr) Vaccin inactive contre la calicivirose feline
IT1233419B (it) Peptidi sintetici immunologicamente attivi utili per la preparazione di un vaccino antimalaria
MD1855G2 (ro) Metodă de imunizare a păsărilor împotriva infecţiilor virale (variante)
UA50800C2 (uk) Спосіб вакцинації тварин від інфекційних захворювань
IT1226728B (it) Coniugato peptidico immunologicamente attivo utile come vaccino antimalaria e metodo di immunizzazione impiegante lo stesso
Dodin et al. Shaba-Zaire choleric epidemy, 1983: Field-trial data on the activity of Institut Pasteur anticholeric oral vaccine.
Flewett Rotaviruses: expectations for a vaccine
Ijaz et al. Potentials of synthetic peptides as rotavirus vaccine and therapy
Vesikari Rotavirus vaccines for prevention of acute gastroenteritis in young infants